Onco-Innovations Strengthens Clinical Leadership with Appointment of Dr. Islam Mohamed as Advisory Board Chair
Onco-Innovations (CBOE CA:ONCO) has appointed Dr. Islam Mohamed as Chair of its Scientific and Clinical Advisory Board. Dr. Mohamed brings over 20 years of experience as a Radiation Oncologist, clinical researcher, and biotechnology advisor.
Dr. Mohamed's expertise spans lung, breast, skin cancers, and sarcoma treatment at BC Cancer, with significant experience in stereotactic radiation delivery. He has led numerous clinical trials and served on research ethics boards and national committees. His role will involve providing strategic guidance on R&D initiatives and facilitating clinical and scientific collaboration.
Onco-Innovations (CBOE CA:ONCO) ha nominato Dr. Islam Mohamed come Presidente del suo Comitato Scientifico e Consulenziale Clinico. Il Dr. Mohamed vanta oltre 20 anni di esperienza come oncologo radioterapista, ricercatore clinico e consulente nel settore biotecnologico.
La sua competenza si estende al trattamento di tumori polmonari, mammari, cutanei e sarcomi presso BC Cancer, con una significativa esperienza nella somministrazione di radioterapia stereotassica. Ha guidato numerosi studi clinici e ha fatto parte di comitati etici per la ricerca e commissioni nazionali. Il suo ruolo consister脿 nel fornire orientamenti strategici sulle iniziative di R&S e nel facilitare la collaborazione clinica e scientifica.
Onco-Innovations (CBOE CA:ONCO) ha designado a Dr. Islam Mohamed como Presidente de su Junta Asesora Cient铆fica y Cl铆nica. El Dr. Mohamed aporta m谩s de 20 a帽os de experiencia como onc贸logo radioter谩pico, investigador cl铆nico y asesor en biotecnolog铆a.
Su experiencia abarca el tratamiento de c谩ncer de pulm贸n, mama, piel y sarcomas en BC Cancer, con una amplia experiencia en la administraci贸n de radioterapia estereot谩ctica. Ha liderado numerosos ensayos cl铆nicos y ha formado parte de juntas de 茅tica en investigaci贸n y comit茅s nacionales. Su funci贸n ser谩 ofrecer orientaci贸n estrat茅gica en iniciativas de I+D y facilitar la colaboraci贸n cl铆nica y cient铆fica.
Onco-Innovations (CBOE CA:ONCO)电� 鞚挫姮霝� 氇晿氅旊摐 氚曥偓毳� 瓿柬暀 氚� 鞛勳儊 鞛愲 鞙勳洂須� 鞚橃灔鞙茧 鞛勲獏頄堨姷雼堧嫟. 氇晿氅旊摐 氚曥偓电� 氚╈偓靹� 膦呾枒頃欖瀽, 鞛勳儊 鞐瓣惮鞛�, 靸濍獏瓿淀暀 鞛愲臧�搿滌劀 20雲� 鞚挫儊鞚� 瓴诫牓鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
攴傅鐢 BC Cancer鞐愳劀 韽愳晹, 鞙犽癌鞎�, 頂茧秬鞎� 氚� 鞙§ 旃橂 攵勳暭鞐� 鞝勲靹膘潉 臧栰稊鞐堨溂氅�, 鞛呾泊 氚╈偓靹� 旃橂 鞝勲嫭鞐� 頀嶋秬頃� 瓴巾棙鞚� 鞛堨姷雼堧嫟. 雼れ垬鞚� 鞛勳儊 鞁滍棙鞚� 欤茧弰頄堨溂氅� 鞐瓣惮 鞙るΜ 鞙勳洂須� 氚� 甑皜 鞙勳洂須岇棎靹� 頇滊彊頄堨姷雼堧嫟. 攴胳潣 鞐暊鞚� 鞐瓣惮臧滊皽 鞝勲灥 歆�旃� 鞝滉车瓿� 鞛勳儊 氚� 瓿柬暀 順戨牓 齑夓鞚� 韽暔頃╇媹雼�.
Onco-Innovations (CBOE CA:ONCO) a nomm茅 Dr Islam Mohamed pr茅sident de son comit茅 consultatif scientifique et clinique. Le Dr Mohamed apporte plus de 20 ans d'exp茅rience en tant qu'oncologue radioth茅rapeute, chercheur clinique et conseiller en biotechnologie.
Son expertise couvre le traitement des cancers du poumon, du sein, de la peau et des sarcomes au BC Cancer, avec une exp茅rience significative dans la d茅livrance de radioth茅rapie st茅r茅otaxique. Il a dirig茅 de nombreux essais cliniques et si茅g茅 dans des comit茅s d'茅thique de la recherche ainsi que dans des commissions nationales. Son r么le consistera 脿 fournir des conseils strat茅giques sur les initiatives de R&D et 脿 faciliter la collaboration clinique et scientifique.
Onco-Innovations (CBOE CA:ONCO) hat Dr. Islam Mohamed zum Vorsitzenden seines Wissenschaftlichen und Klinischen Beirats ernannt. Dr. Mohamed bringt 眉ber 20 Jahre Erfahrung als Strahlenonkologe, klinischer Forscher und Biotechnologieberater mit.
Seine Expertise umfasst die Behandlung von Lungen-, Brust-, Hautkrebs und Sarkomen am BC Cancer, mit umfangreicher Erfahrung in der stereotaktischen Strahlenbehandlung. Er hat zahlreiche klinische Studien geleitet und war in Forschungsethikkomitees sowie nationalen Gremien t盲tig. Seine Aufgabe wird es sein, strategische Beratung zu F&E-Initiativen zu geben und klinische sowie wissenschaftliche Zusammenarbeit zu f枚rdern.
- Appointment of highly experienced radiation oncologist with over 20 years of expertise
- Strategic addition to enhance R&D capabilities and clinical trial expertise
- Dr. Mohamed brings valuable experience in biotech venture advisory and investment
- None.
VANCOUVER, BC / / July 10, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce the appointment of Dr. Islam Mohamed as Chair of its Scientific and Clinical Advisory Board. This appointment reflects the Company's commitment to scientific excellence and its mission to accelerate the development of innovative oncology solutions through expert-led translational research.
Dr. Islam Mohamed is an experienced Radiation Oncologist, clinical researcher, and biotechnology advisor who has spent over two decades operating at the intersection of oncology and innovation. After earning an Honours BSc in Genetics, he pursued a career in Medicine, completing his specialty training in Radiation Oncology in 2000. At BC Cancer, he has built a distinguished clinical career focused on lung, breast, skin cancers, and sarcoma, and is recognized for his expertise in stereotactic radiation delivery.
Dr. Mohamed has led numerous clinical trials at both local and provincial levels, contributing to advances in the treatment of breast, lung, and oligometastatic cancers. He has also served on research ethics boards and national clinical trial committees, shaping standards of care and clinical research strategy in Canada.
Complementing his clinical leadership, Dr. Mohamed brings deep insight into the health technology ecosystem. He advises and invests in emerging Canadian biotech ventures, including Linax Technologies, IllumiSonics, and Asep Medical, with a focus on companies developing transformative diagnostics, therapeutics, and platform technologies. His combined experience as a clinician, researcher, and entrepreneur positions him as a strategic asset in evaluating innovation, guiding translational research, and driving value creation.
The Scientific and Clinical Advisory Board plays a critical role in supporting Onco-Innovations' research and development (R&D) priorities. Its mandate is to provide strategic guidance on R&D initiatives, facilitate clinical and scientific collaboration among partners, and support the mobilization of knowledge and generation of independent scientific insights to guide decision-making.
"We are thrilled to welcome Dr. Mohamed as Chair of our Scientific and Clinical Advisory Board. His deep clinical insight, research leadership, and strategic involvement in biotech innovation will be instrumental as we advance our oncology pipeline and translational research initiatives," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
[email protected]
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, PROmAI, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies, the failure to realize the anticipated benefits of PROmAI and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original on ACCESS Newswire
FAQ
Who is Dr. Islam Mohamed and what is his new role at Onco-Innovations (ONNVF)?
What is Dr. Islam Mohamed's clinical experience and expertise?
How will Dr. Mohamed's appointment benefit Onco-Innovations (ONNVF)?
What companies has Dr. Mohamed advised or invested in previously?
